New cancer drug LM-108 tested in humans for first time
NCT ID NCT05199753
Summary
This was the first study in people to test a new drug called LM-108 for advanced solid tumors. It involved 78 adults whose cancer had progressed despite standard treatments. The main goals were to find a safe dose and see if the drug, given alone or with an immunotherapy, showed any early signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Hospital
Melbourne, Victoria, VIC 3004, Australia
-
Blacktown Hospital
Sydney, New South Wales, NSW 2148, Australia
-
Cabrini Health Limited
Malvern, Victoria, VIC 3144, Australia
-
ICON Cancer Centre
South Brisbane, Queensland, QLD 4101, Australia
-
One Clinical Research Pty Ltd.
Nedlands, Western Australia, WA 6009, Australia
-
Sunshine Coast University Private Hospital
Birtinya, Queensland, QLD 4575, Australia
Conditions
Explore the condition pages connected to this study.